PLUS1
33.065
-1.01 (-2.95%)
-1.01 (-2.95%)
Upgrade to Real-Time
Regular Market
Low
28.58
High
71.45
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| uniQure NV | QURE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.01 | -2.95% | 33.065 | 15:33:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 34.05 | 32.865 | 34.60 | 34.07 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 33.02 | 33.11 | 0.09 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,926 | 190,970 | $ 33.39 | $ 6,376,040 | 637,117 | 28.58 - 71.45 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:34:08 | 100 | $ 33.065 | USD |
uniQure NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.47B | 44.50M | 44.28M | $ 7.28M | $ - | -3.12 | -10.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
uniQure NV News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/16/2021 | 11:55 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/08/2021 | 08:28 | Seeking Alpha | uniQure reports preclinical data for AMT-130 in Huntington’s.. |
| 4/08/2021 | 07:05 | GlobeNewswire Inc. | uniQure Announces Publications of Preclinical Data for.. |
| 4/05/2021 | 21:54 | TipRanks | These 2 Stocks Look Poised for a Turnaround, Say Analysts |
| 4/05/2021 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/05/2021 | 07:32 | Seeking Alpha | uniQure completes enrollment in first cohort of early-stage.. |
| 4/05/2021 | 07:05 | GlobeNewswire Inc. | uniQure Announces Completion of Enrollment in First Cohort.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QURE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 33.51 | 36.115 | 32.52 | 34.52 | 283,714 | -0.445 | -1.33% |
| 1 Month | 33.29 | 36.48 | 28.58 | 32.75 | 472,046 | -0.225 | -0.68% |
| 3 Months | 39.51 | 40.4899 | 28.58 | 34.68 | 475,081 | -6.45 | -16.31% |
| 6 Months | 36.11 | 52.19 | 28.58 | 38.87 | 490,955 | -3.05 | -8.43% |
| 1 Year | 55.82 | 71.45 | 28.58 | 43.65 | 490,783 | -22.76 | -40.76% |
| 3 Years | 31.50 | 82.49 | 21.98 | 48.63 | 482,579 | 1.57 | 4.97% |
| 5 Years | 13.43 | 82.49 | 4.72 | 38.19 | 413,171 | 19.64 | 146.2% |
uniQure NV Description
| uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers-Squibb for cardiovascular diseases. |
